Abstract:IntroductionDespite curative resection of early-stage Non-Small Cell Lung Cancer (NSCLC), many patients can experience recurrence and are thus subjected to surveillance with repeated imaging tests. We aimed to understand the cellular metabolic processes involved in tumor initiation, progression, and metastasis. We hypothesized that non-invasive monitoring of urinary metabolites would allow the detection of metabolic changes in response to treatment and can thereafter be used for surveillance of recurrence. Our current study aimed to assess the changes in urinary metabolites in response to surgical removal of the tumor.MethodsIn this prospective cohort study, urine was collected before and after surgical resection from patients with early-stage NSCLC. It was analyzed for a change in their metabolic profile using Liquid chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-QTOF-MS). Patients with biopsy-proven NSCLC, a PET-avid pulmonary nodule, or an enlarging nodule on serial CT scans of the chest with clinical stage I/II eligible for resection were prospectively enrolled. Mid-stream urine was collected pre-operatively and within four months post-operatively. Metabolic data was acquired on a 1260 Infinity HPLC coupled to a 6538 UHD Accurate Q-TOF MS system equipped with an electrospray ionization source. Surgical pathology for each patient was reviewed, and only patients with confirmed NSCLC were included for analysis. Fold change was assessed with paired T-tests (P<0.05; ≥ 2-fold changes) employing an asymptotic P-value and multiple testing correction (Benjamini-Hochberg). Mass Professional Profiler software was used to identify urinary metabolites of statistical significance, and their up/down regulation was recorded. This was further confirmed with mass spectra, retention time, and confidence scores against the Metlin database containing >79,000 metabolites, 39,000 lipids, and 168,000 peptides.ResultsThirty-six patients with clinical stage I/II pathologically-confirmed NSCLC who provided urine samples before and after surgical resection were analysed. Mean age was 64.9 years (SD=7.4). There were 22 females (61.1%) and 14 males (38.9%). Smoking history was as follows: current smokers (n=10), ex-smoker or never smoked (n=20), no history available (n=6). Six patients had diabetes and 17 patients had COPD. Distribution of histology was: adenocarcinoma (n=29), squamous cell cancer (n=5), and other (n=2). Mean tumor size on pre-operative CT was 2.4 cm (SD=1.6); mean tumor size from pathology specimens was 2.7 cm (SD=1.8). Mean PETSUV was 8.2 (SD=6.4). Twenty-nine urinary metabolic compounds were significantly different between their pre-surgery and post-surgery levels. Twenty-one compounds were over-expressed before surgical resection with a significant decline after resection. 8/29 compounds were significantly elevated after resection. Notably Proline-Leucine was significantly over expressed at pre surgery level with the following Log 2 values: pre surgery level of 11.22 vs. post-surgery1.93 (P<0.0001). Asymmetric dimethyl arginine (ADMA) pre surgery level of 8.10 vs. post-surgery 4.12 P=0.044). N6-Methyladenosine was significantly upregulated post-surgical resection with pre surgery level of 3.51 vs. 8.25 (P=0.0085).ConclusionTesting of urinary metabolites showed that Proline-Leucine over-expression pre-operatively was significantly reduced after removal of lung cancer. Proline, glutamic acid- and leucine-rich protein-1 has been found to be associated with NSCLC. Our study has identified a non-invasive potential panel of biomarkers for NSCLC and requires larger clinical studies for confirmation.KeywordsMetabolism, lung cancer, Mass Spectrometry IntroductionDespite curative resection of early-stage Non-Small Cell Lung Cancer (NSCLC), many patients can experience recurrence and are thus subjected to surveillance with repeated imaging tests. We aimed to understand the cellular metabolic processes involved in tumor initiation, progression, and metastasis. We hypothesized that non-invasive monitoring of urinary metabolites would allow the detection of metabolic changes in response to treatment and can thereafter be used for surveillance of recurrence. Our current study aimed to assess the changes in urinary metabolites in response to surgical removal of the tumor.

Preoperative Metabolic Signatures of Prostate Cancer Recurrence Following Radical Prostatectomy.

Ultra-Performance Liquid Chromatography Coupled with Quadrupole Time-Of-Flight Mass Spectrometry-Based Metabolic Profiling of Human Serum Prior to and Following Radical Resection of Colorectal Carcinoma

Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles.

P62.04 Metabolic Profile of Urine of Early Stage Non Small Cell Lung Cancer Patients Before and after Surgical Resection Using Mass Spectrometry

Metabolomic Footprints of Lethal Versus Indolent Prostate Cancer

Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer

Untargeted urine metabolite profiling by mass spectrometry aided by multivariate statistical analysis to predict prostate cancer treatment outcome

Comparison of the metabolome in urine prior and eight weeks after radical prostatectomy uncovers pathologic and molecular features of prostate cancer

Predicting ovarian cancer recurrence by plasma metabolic profiles before and after surgery

Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification

A Metabolism-Related Gene Landscape Predicts Prostate Cancer Recurrence and Treatment Response

An NMR-based metabolic signature to identify clinically significant prostate cancer in patients undergoing biopsy

Metabolic Response to Preoperative Chemotherapy Predicts Prognosis for Patients Undergoing Surgical Resection of Colorectal Cancer Metastatic to the Liver

Preoperative Multiparametric Magnetic Resonance Imaging Based Risk Stratification System for Predicting Biochemical Recurrence After Radical Prostatectomy

Metabolic Syndrome and Its Components Predict the Biochemical Recurrence and Adverse Pathological Features of Patients Following Radical Prostatectomy: a Propensity Score Matching Study

A Pilot Study of Gas Chromatograph/Mass Spectrometry-Based Serum Metabolic Profiling of Colorectal Cancer after Operation

Bi-Parametric Magnetic Resonance Imaging Analysis of Biochemical Recurrence of Prostate Cancer after Radical Surgery and Its Predictive Value: A Retrospective Study

Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients

Development and Validation of a Multimodality Model Based on Whole-Slide Imaging and Biparametric MRI for Predicting Postoperative Biochemical Recurrence in Prostate Cancer.

Metabolic Changes in Early-Stage Non–Small Cell Lung Cancer Patients after Surgical Resection